Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Inflammatory Bowel Diseases

Free Subscription 13.07.2026 2 Aliment Pharmacol Ther 3 BMC Gastroenterol 1 Clin Gastroenterol Hepatol 2 Eur J Gastroenterol Hepatol 2 Gastroenterol Hepatol 1 Gastroenterology 3 Gut 9 Inflamm Bowel Dis 5 J Crohns Colitis 1 PLoS One 2 Scand J Gastroenterol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Aliment Pharmacol Ther

1. YOUNG D, Booker C, Samaan M, Kok K, et al
   Real-World Effectiveness, Safety and Quality of Life With Ustekinumab for the Treatment of Crohn's Disease: Results of the UK Ustekinumab Real World Evidence Study (UndieS) Study Group.
   Aliment Pharmacol Ther. 2026 Jul 9. doi: 10.1111/apt.70833.
   PubMed         Abstract available
   
   
2. ZHU A, Segal JP
   Letter: Nuanced Interpretation of Faecal Calprotectin During Maintenance of Ulcerative Colitis Treatment: Sweet Spots and Pitfalls.
   Aliment Pharmacol Ther. 2026 Jul 9. doi: 10.1111/apt.70839.
   PubMed        
   
   

   
   BMC Gastroenterol

3. THOMANN AK, Schmitgen MM, Stephan JC, Knoedler LL, et al
   Brain network correlates of fatigue, depression, and anxiety in patients with Crohn's Disease in different disease states.
   BMC Gastroenterol. 2026 Jul 9. doi: 10.1186/s12876-026-05097.
   PubMed         Abstract available
   
   
4. YU Z, Duan R, Liu Q, Mei W, et al
   Comparison of six nutritional screening tools for identifying BMI?defined malnutrition in patients with Crohn's disease: a cross?sectional study.
   BMC Gastroenterol. 2026 Jul 8. doi: 10.1186/s12876-026-05042.
   PubMed         Abstract available
   
   
5. XU S, Wen M, Yang A, Ma X, et al
   Diagnostic efficacy of pan-immune inflammation value for ulcerative colitis activity: a study based on multi-indicator comparison and diagnostic grey zone validation.
   BMC Gastroenterol. 2026 Jul 7. doi: 10.1186/s12876-026-05082.
   PubMed         Abstract available
   
   

   
   Clin Gastroenterol Hepatol

6. VUIJK SA, Jongsma MME, Cozijnsen MA, van Pieterson M, et al
   Randomized trial comparing 5-year follow-up of first-line infliximab to conventional therapy in paediatric Crohn's disease.
   Clin Gastroenterol Hepatol. 2026 Jul 4:S1542-3565(26)00488.
   PubMed         Abstract available
   
   

   
   Eur J Gastroenterol Hepatol

7. INCE OZGENEL F, Tulek Z, Temel T
   Effect of a nurse-led individualized patient education program on fatigue and quality of life in patients with inflammatory bowel disease.
   Eur J Gastroenterol Hepatol. 2026 Jun 29. doi: 10.1097/MEG.0000000000003241.
   PubMed         Abstract available
   
   
8. GIRI S, Kulkarni A, Harindranath S, Malakar S, et al
   Comparative efficacy of advanced therapies in biological-exposed ulcerative colitis - a network meta-analysis of randomized trials.
   Eur J Gastroenterol Hepatol. 2026 Jun 29. doi: 10.1097/MEG.0000000000003240.
   PubMed         Abstract available
   
   

   
   Gastroenterol Hepatol

9. ELOSUA A, Zabalza L, Vicuna M, Rubio S, et al
   Early real-world effectiveness of mirikizumab in a difficult-to-treat ulcerative colitis cohort.
   Gastroenterol Hepatol. 2026 Jul 7:502833. doi: 10.1016/j.gastrohep.2026.502833.
   PubMed        
   
   
10. MARTINEZ-CUEVAS C, Morera-Sauca L, Madrigal RE, Barrio J, et al
    Effectiveness and safety of Ustekinumab in older patients with Crohn s disease with high comorbidity burden: a real-world study.
    Gastroenterol Hepatol. 2026 Jul 7:502831. doi: 10.1016/j.gastrohep.2026.502831.
    PubMed         Abstract available
    
    

    
    Gastroenterology

11. CESAR DA SILVA B, Noor NM
    Two trials with two different answers: potential for Bayesian re-analysis in a Crohn's disease clinical trial.
    Gastroenterology. 2026 Jul 9:S0016-5085(26)07056.
    PubMed        
    
    

    
    Gut

12. COLWILL M, Honap S, Young AM, Magro F, et al
    Digital twins in IBD-bridging data, biology and trial innovation.
    Gut. 2026;75:1607-1619.
    PubMed         Abstract available
    
    
13. YALCINKAYA A, Sandstrom E, Degrace EJ, Pigneur B, et al
    IL-10-neutralising autoantibodies in paediatric-onset inflammatory bowel disease.
    Gut. 2026 Jul 8:gutjnl-2026-338876. doi: 10.1136/gutjnl-2026-338876.
    PubMed         Abstract available
    
    
14. WANG D, Zhao X, Yang Q, Zhu D, et al
    SMOC2 mediates GLI1+ mesenchymal cell-driven fibrostenosis and predicts postoperative recurrence in Crohn's disease.
    Gut. 2026 Jul 8:gutjnl-2025-337952. doi: 10.1136/gutjnl-2025-337952.
    PubMed         Abstract available
    
    

    
    Inflamm Bowel Dis

15. BRONZE S, Ibing S, Jimenez D, Mercedes PR, et al
    Fecal calprotectin is an accurate noninvasive screening tool for pouchitis.
    Inflamm Bowel Dis. 2026;32:1298-1303.
    PubMed         Abstract available
    
    
16. DESTER E, Powers JC, Zemanek M, Smith R, et al
    Preoperative anorectal manometry is associated with cuffitis but not proximal pouch inflammation after IPAA creation.
    Inflamm Bowel Dis. 2026;32:1248-1255.
    PubMed         Abstract available
    
    
17. DUBINSKY MC, Schreiber S, Yarur AJ, Sands BE, et al
    Recovery of response and long-term outcomes following loss of response and dose escalation of subcutaneous infliximab: a post hoc analysis of the LIBERTY-CD & LIBERTY-UC trials.
    Inflamm Bowel Dis. 2026;32:1235-1247.
    PubMed         Abstract available
    
    
18. YOON J, Jun YK, Lee HS, Yoo JH, et al
    Early immunomodulator therapy reduces the risk of intestinal resection in Crohns disease: a systematic review and meta-analysis.
    Inflamm Bowel Dis. 2026;32:1333-1343.
    PubMed         Abstract available
    
    
19. LEDDY RS, Hudachek CL, Phelan HM, Aherne CM, et al
    CB2R promotes T cell gut homing and exacerbates ileitis in a murine Crohn's model.
    Inflamm Bowel Dis. 2026;32:1219-1234.
    PubMed         Abstract available
    
    
20. FAYE AS, Kochar B, Choi D, Gift T, et al
    Inflammatory bowel disease in the aging population.
    Inflamm Bowel Dis. 2026 Jul 8:izag122. doi: 10.1093.
    PubMed         Abstract available
    
    
21. DEL GAUDIO A, Di Vincenzo F, Cuccia G, Coppola G, et al
    Timing of biologic prophylaxis and postoperative recurrence in Crohn's disease: A real-life cohort study using propensity score weighting.
    Inflamm Bowel Dis. 2026 Jul 8:izag130. doi: 10.1093.
    PubMed         Abstract available
    
    
22. SUSKIND DL, Hoffman LR, Lee D, Verster AJ, et al
    Metabolome remodeling with reverse-engineered exclusive enteral nutrition in children with active Crohn's disease.
    Inflamm Bowel Dis. 2026 Jul 8:izag095. doi: 10.1093.
    PubMed         Abstract available
    
    
23. SAFARI K, Ma WJ, Sekhon P, Rai P, et al
    Mast cell-derived IL-13 as a driver of Crohn disease-associated intestinal fibrosis.
    Inflamm Bowel Dis. 2026 Jul 8:izag127. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Crohns Colitis

24. RYTTER H, Chevarin C, Martin L, Bruder E, et al
    Dietary emulsifiers and host inflammation synergistically drive genomic evolution of Crohn's disease-associated Escherichia coli toward enhanced pathogenicity.
    J Crohns Colitis. 2026;20:jjag088.
    PubMed         Abstract available
    
    
25. GU B, Kariyawasam V, Leong RW
    Off-label upadacitinib 60 mg daily in the rescue of refractory ulcerative colitis: an open-labeled cohort study.
    J Crohns Colitis. 2026;20:jjag091.
    PubMed        
    
    
26. YANAI H, Ellul P, Verstockt B, Greuter T, et al
    ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease.
    J Crohns Colitis. 2026;20:jjag071.
    PubMed        
    
    
27. JAGHULT S, Adamina M, Farrell D, Bager P, et al
    Third N-ECCO Consensus Statements on the Nursing Roles in Caring for Patients with Inflammatory Bowel Disease.
    J Crohns Colitis. 2026;20:jjag054.
    PubMed        
    
    
28. GISBERT JP, Chaparro M, Verstockt B, Kienle P, et al
    ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment.
    J Crohns Colitis. 2026;20:jjag066.
    PubMed        
    
    

    
    PLoS One

29. LI Y, Hua Q, Li Z, Jiang M, et al
    Association between hemoglobin-to-red cell distribution width ratio and occurrence of sepsis during ICU stay in inflammatory bowel disease patients who died: a retrospective study using the EICU-CRD database.
    PLoS One. 2026;21:e0353237.
    PubMed         Abstract available
    
    

    
    Scand J Gastroenterol

30. ANDERSEN JW, Troelsen FS, Krogh K, Hart A, et al
    Diverging incidences of low-grade dysplasia and advanced neoplasia in inflammatory bowel disease: a nationwide Danish cohort study.
    Scand J Gastroenterol. 2026 Jul 9:1-10. doi: 10.1080/00365521.2026.2698840.
    PubMed         Abstract available
    
    
31. LE BRETON S, Mithal A, Ahmed T, Huh J, et al
    Assessing trial eligibility and real-world response to vedolizumab and ustekinumab in patients with ulcerative colitis.
    Scand J Gastroenterol. 2026 Jul 6:1-7. doi: 10.1080/00365521.2026.2697982.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum